

1 **Phenotypic presentation of family members of ATTRv probands and subsequent disease**
2 **penetrance**

3
4 Luca Fazzini, MD* ; Matteo Castrichini, MD* ; Yan Li, PhD; Jose De Melo Jr, MD; Marta
5 Figueiral, MD; Jenny J. Cao, MB; Eric W. Klee, MD; Christian Cadeddu Dessalvi, MD PhD;
6 Martha Grogan, MD; Angela Dispenzieri, MD; Naveen L. Pereira, MD

7
8 *These authors share first authorship

9
10 **Affiliations:** Department of Cardiovascular Medicine (L.F., M.C., J.DM.Jr, M.F., J.J.C., M.G.,
11 N.L.P.); Department of Quantitative Health Science, Division of Clinical Trials and Biostatistics
12 (Y.L.); Department of Quantitative Health Science, Division of Computational Biology (E.W.K.);
13 Division of Hematology (A.D.), Mayo Clinic, Rochester, MN. Department of Medical Sciences
14 and Public Health, University of Cagliari, Cagliari, Italy (L.F, C.C.D.).

15
16 **Short title:** ATTRv genetic carriers – phenotype and outcomes

17
18 **Corresponding Author:**

19 Naveen L. Pereira, MD; Department of Cardiovascular Medicine and Department of Molecular
20 Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester,
21 MN, 55905. Email: pereira.naveen@mayo.edu; Twitter @nl_pereira

22 **Abstract**

23 **BACKGROUND:** Hereditary transthyretin amyloid cardiomyopathy (ATTRv-CM) is being
24 increasingly diagnosed due to enhanced awareness and availability of newer therapeutics.
25 Multiple *TTR* variants have been described worldwide, but with uncertain disease penetrance.
26 The characteristics and outcomes of “previously undiagnosed” pathogenic-likely pathogenic
27 (P/LP) *TTR* variant (genotype or G+; cardiac phenotype or P-) carriers are unknown which has
28 important prognostic and therapeutic implications, especially for affected family members. This
29 descriptive study aimed to delineate phenotype and cardiac penetrance in “previously
30 undiagnosed” G+P- family members of ATTRv probands.

31 **METHODS:** Demographic, electrocardiographic (ECG), genetic, and imaging
32 (echocardiography, cardiac technetium-99m pyrophosphate (PYP) and magnetic resonance
33 imaging) data were analyzed. The prediction effect of selected baseline characteristics for
34 ATTRv-CM development was evaluated. Kaplan-Meier and Cox regression methods were used
35 to describe risk and predictors of ATTRv-CM development in family members.

36 **RESULTS:** There were 85 G+P- family members identified. Mean age was 48.5±11.7 years,
37 39% were male, 18% had a diagnosis of peripheral neuropathy, 15% with a history of carpal
38 tunnel syndrome, and 4% had atrioventricular block at baseline. Of these, 55 patients had follow-
39 up imaging studies. After a median 6.8-year follow-up, 22% developed ATTR-CM with a 10-
40 year estimated risk of 29.5% (95% CI 7.9-46.0). Cardiac penetrance increased with increasing
41 family member's age. Proband’s diagnosis age ($p=0.0096$) and artificial intelligence (AI)-ECG
42 prediction ($p=0.0091$) were promising baseline predictors of time to ATTRv-CM development.

43 **CONCLUSION:** In previously undiagnosed G+P- ATTRv family members, the incidence of
44 subsequent CM is high. Predictors for CM development such as proband's diagnosis age and AI-
45 determined ECG probability of ATTR-CM require further investigation.

46

47 **Keywords:** transthyretin amyloidosis; phenotype; cardiac; cardiomyopathy

48

49 **NON-STANDARD ABBREVIATIONS AND ACRONYMS**

| | | |
|----|-------------|----------------------------|
| 50 | AI | artificial intelligence AI |
| 51 | ATTR | transthyretin amyloidosis |
| 52 | AUC | area under the curve |
| 53 | CA | cardiac amyloidosis |
| 54 | CI | confidence interval |
| 55 | CM | cardiomyopathy |
| 56 | CV | cross-validation |
| 57 | cMRI | cardiac magnetic resonance |
| 58 | ECG | electrocardiographic |
| 59 | HR | hazards ratio |
| 60 | LV | left ventricular |
| 61 | PR | precision recall |
| 62 | PYP | pyrophosphate |

63

64

65 **Introduction**

66 Cardiac amyloidosis (CA) is a well-known cause of heart failure and life-threatening disease.¹⁻³
67 Early diagnosis of transthyretin amyloidosis (ATTR) which is a common cause of CA has
68 become especially relevant given recent advances in diagnosis and therapy.⁴ Cardiomyopathy
69 (CM) due to ATTR is classified as either wild-type (ATTRwt-CM) or hereditary (ATTRv-CM).⁵
70 Hereditary ATTR is an autosomal-dominant disease and over 130 *TTR* variants have been
71 identified that have ethnic and geographical specific distribution.⁶⁻⁸ Different *TTR* genotypes are
72 associated with varying phenotypes.⁹⁻¹¹ The correlation between genetic heterogeneity,
73 variability in disease onset, and expression remains an active area of investigation.¹²

74 Genetic testing is recommended in patients diagnosed with ATTR-CM in order to
75 distinguish between wild-type and hereditary disease.^{4,13-15} Identifying a pathogenic (P) or likely-
76 pathogenic (LP) variant not only enables a diagnosis of ATTRv-CM but also allows for cascade
77 testing in first-degree relatives.¹⁶ However, managing genotype-positive (G+, carriers of a P or
78 LP variant) phenotype-negative (P-, individuals without evidence of structural heart disease)
79 remains a challenge due to a lack of information on the natural course of the disease and the
80 uncertain cardiac penetrance of these *TTR* variants. Understanding outcomes and identifying
81 high risk individuals will inform strategies for not only monitoring but also potentially treating
82 *TTR* genetic (G+P-) carriers. The purpose of this study was to evaluate the natural history,
83 cardiac disease penetrance, and predictors of the development of ATTRv-CM in previously
84 undiagnosed *TTR* G+P- individuals.

85

86 **Methods**

87 *Study population*

88 The institutional review board of the Mayo Clinic Foundation approved this study which was a
89 single-center, observational, and retrospective study. Among the overall population affected by
90 amyloidosis followed at Mayo Clinic, Rochester, previously undiagnosed family members of
91 probands who were diagnosed with ATTRv and underwent genetic testing were identified from
92 January 1998 to October 2023. Those with P/LP *TTR* variants without evidence of ATTR-CM at
93 baseline screening (G+P-) were included in the study. P- individuals were defined as those with
94 the absence of echocardiographic evidence of ATTR-CM as previously described¹⁷ and/or
95 negative pyrophosphate (PYP) scintigraphy. Pertinent demographic, clinical,
96 electrocardiographic (ECG), and imaging data closest to the date of genetic testing for these
97 patients were extracted from the electronic medical record. Patients without cardiac imaging at
98 baseline were excluded since the baseline cardiac phenotype could not be determined. The
99 population was divided into two groups based on the development of CM during follow-up.

100

101 *Genetic testing*

102 Genomic DNA obtained from submitted samples was enriched for targeted regions using a
103 hybridization-based protocol. Sequence analysis and deletion/duplication testing of the *TTR* gene
104 were performed. A bi-directional sequence analysis was performed to test for the presence of
105 variants in all coding regions and intron/exon boundaries of the *TTR* gene. A P/LP variant in the
106 *TTR* gene was defined as per the American College of Medical Genetics and Genomics (ACMG)
107 standard criteria.¹⁸

108

109 *Cardiomyopathy diagnosis during follow-up*

110 The criteria used to diagnose ATTR-CM during follow-up were as follows: 1) Standard
111 previously used echocardiographic criteria (at least two of the following features):¹⁷ normal left
112 ventricular (LV) wall thickness at baseline ($\leq 13\text{mm}$) that became abnormal during follow-up;
113 normal filling pressures ($E/e' \leq 8$) that became abnormal, normal atria size at baseline that
114 evolved to biatrial enlargement at follow-up; and normal LV global longitudinal strain ($< -18\%$)
115 that subsequently became abnormal. 2) a normal cardiac magnetic resonance (cMRI) scan at
116 baseline which during follow-up demonstrated late gadolinium enhancement and increased
117 extracellular volume consistent with ATTR-CM 3) a negative baseline PYP scintigraphy that
118 became positive during follow-up. Patients were considered not to have developed ATTR-CM if
119 they had any negative follow-up imaging study.

120

121 *Artificial intelligence-enabled electrocardiography*

122 A previously developed and validated artificial intelligence (AI) algorithm to diagnose CA was
123 applied to the baseline ECG of the G+P- carriers.^{19,20} An AI ECG was considered positive when
124 the probability threshold to detect patients with CA by the Youden index was 0.485 or higher.

125

126 *Statistical analysis*

127 Descriptive statistics were used to summarize the characteristics of the study population.
128 Continuous variables are reported as mean (standard deviation, SD) or median (interquartile
129 range [IQR]), and categorical variables are reported as proportions. To evaluate if clinical and
130 echocardiographic characteristics are changed between baseline and follow-up, continuous
131 variables were tested using paired two-sided t-tests, while binary variables were tested if their

132 proportional difference between baseline and follow-up is different from 0. Kaplan-Meier
133 method was used to estimate time-to-event models. Patients without events were censored at the
134 last follow-up. To study the prediction effect of selected baseline characteristics, first we fit the
135 Firth's penalized logistic regressions using the CA development as a dependent variable and the
136 baseline characteristics as independent variables. Next, we aimed to study if there is a synergistic
137 effect of those baseline variables. To retain the sample size of 55, missing values of baseline
138 variables were imputed by median values from corresponding groups (developing or not
139 developing CA). Next, we combine these selected baseline characteristics using Ridge logistic
140 regression. Therefore, the predictor of this Ridge logistic model is the optimal composite score of
141 those baseline variables. We used precision-recall (PR) curve analysis to evaluate the predicting
142 effect of the composite score for CA development. Specifically, 11-fold cross-validation (CV)
143 was used when calculating the area under the curve (AUC), since the score was derived from an
144 estimated model and was needed to protect against overfitting. To improve the estimated
145 performance of the regression model, we repeated the CV procedure 100 times. Univariable Cox
146 proportional hazard models were performed to evaluate the risk of developing overt CA. The
147 Hazard Ratios (HR) and the corresponding 95% Confidence Intervals (CI) were reported. The
148 *TRR* penetrance on ATTR-CM in different age groups were calculated and their 95% CI were
149 estimated. For all tested hypotheses, the significance level of 0.05 was considered and multiple
150 testing was adjusted by the Bonferroni correction method. All analyses were performed on R
151 version 4.2.2.

152

153 **Results**

154 Among the overall ATTR population reviewed (n=1802), 85 carriers were confirmed to have
155 P/LP TTR variants without evidence of CM at the time of genetic testing. Specifically, 80
156 patients had normal echocardiography and 5 patients had negative PYP scintigraphy alone, 29
157 patients had both negative echocardiography and PYP scintigraphy. In addition, cMRI at baseline
158 was normal in 4 patients.

159

160 *Baseline characteristics of TTR genotype-positive phenotype-negative individuals*

161 Baseline characteristics of the patient population are reported in **Table 1**. The mean age was
162 48.5 ± 11.7 years, 39% were males, and 91% were White. Comorbidities included spinal stenosis
163 (2%), chronic kidney disease (1%), peripheral neuropathy (18%), and bilateral carpal tunnel
164 syndrome (15%). One patient had undergone permanent pacemaker implantation and 2% had a
165 prior history of syncope. Troponin levels were elevated in 17% of patients, and median NT-
166 proBNP in the cohort was normal at 51 pg/ml (IQR 25-88). ECG abnormalities included
167 atrioventricular block (n=3), atrial fibrillation (n=3), low voltage (n=1) and pseudo-infarct
168 pattern (n=3). The median AI-enabled ECG probability of CA was 6.3% (IQR 1.9-19.3), and five
169 patients had an AI-ECG probability above the threshold.

170 None of the patients met the pre-defined echocardiographic criteria for ATTR-CM. Mean
171 septal and posterior wall thickness were 9.3 ± 1.5 and 9.1 ± 1.4 mm respectively with a mean LV
172 end-diastolic volume of 127 ml and LV ejection fraction (LVEF) of $62.6 \pm 7.4\%$. A sensitive
173 indicator of systolic dysfunction, LV global longitudinal strain was slightly reduced (range -15%
174 to -17%) in 11% of patients (n=7/61) but overall mean values were normal at $-20.5 \pm 2.6\%$. Left

175 atrial dilation was reported in 10% of subjects with a mean left atrium volume index that was
176 normal at 28 ± 8.5 ml/m². Mean LV filling pressures were not significantly elevated (7.7 ± 2.7).
177 The *TTR* P/LP variants observed in our population are listed in **Table S1** with Val30Met being
178 the most prevalent (30%), followed by Thr60Ala (28%), Val122Ile (9%), and Ile107Val (7%).

179

180 *Clinical progression in TTR genotype-positive phenotype-negative carriers*

181 Among the 85 G+/P- carriers, follow-up clinical and imaging studies were available in 55
182 patients. Clinical progression in this cohort is described in **Table 2**. Over a median follow-up
183 period of 6.8 years (IQR 4.1 – 9.7), the risk of developing peripheral neuropathy during follow-
184 up was 25.5% (95%CI: 8.9, 42.1) as compared to baseline ($p=0.004$). Specifically, there were an
185 additional 4 patients who developed spinal stenosis, 7 bilateral carpal tunnel syndrome, 5 atrial
186 fibrillation, and 6 syncope during follow-up as compared to baseline. Among the patients ($n=24$)
187 who were diagnosed with peripheral neuropathy, 15 underwent skin/nerve biopsy, and 2 patients
188 stained positive for amyloid deposition. Small interfering RNA or antisense oligonucleotide
189 therapy was initiated in 12 patients.

190

191 *Cardiac disease penetrance in TTR genotype-positive phenotype-negative carriers*

192 Within this group, 53 underwent echocardiography, and 2 patients had a PYP scan alone, 18 had
193 both PYP scintigraphy and echo, and 4 had both cMRI and echo at baseline. During follow-up,
194 12 (22%) of the 55 patients developed ATTRv-CM. Specifically, 5 patients developed a positive
195 PYP scan, 6 patients were diagnosed based on the change in predefined echocardiography
196 criteria and 1 patient developed cMRI features of CA. The disease-free at 10 years was estimated
197 by the Kaplan-Meier method, and the 10-year risk of developing overt ATTRv-CM was 29.5%

198 (95% CI: 7.9, 46.0, **Figure 1**). Additionally, cardiac penetrance was assessed among different
199 age groups (**Table 3**). The penetrance increases as age increases. For the groups ≤ 50 years, 50-
200 60 years, 60-70 years, and > 70 years, there are 11% (95% CI: 3%, 33%), 13% (95% CI: 4%,
201 38%), 33% (95% CI: 15%, 58%), and 43% (95% CI: 16%, 75%) patients developed ATTRv-CM
202 at the end of the follow-up period, respectively. We also studied cardiac penetrance among
203 different genetic variants. The age distribution is similar among the three most prevalent variants.
204 The median ages at the end of follow-up are 61.0, 60.5, and 59.0 for patients who have
205 Val130Met, Thr60Ala, and Val122Ile variants, respectively. The cardiac penetrance for the three
206 genetic variants are 7% for Val130Met, 33% for Thr60Ala, and 40% for Val122Ile (**Table S2**).
207

208 *Echocardiographic changes in TTR genotype-positive phenotype-negative carriers*

209 Echocardiographic progression in this cohort is described in **Table 2**. Overall, we observed a
210 decrease in LVEF ($p=0.014$), an increase in septal wall thickness ($p=0.037$), and an increase in
211 left atrium dilation proportion ($p=0.016$). Posterior wall thickness, left atrium volume index,
212 bilateral dilation, E/e' , and LV GLS did not significantly change. Notably, while at baseline no
213 patients had abnormal wall thickness, 4 patients had abnormal septal wall thickness and 2
214 patients had abnormal posterior wall thickness during follow-up.

215 In the 12 patients diagnosed with ATTRv-CM (**Table 4**), the mean LVEF remained
216 normal ($60.3 \pm 5.3\%$) but was reduced as compared to baseline ($p=0.026$). There was an increase
217 in the mean septal wall (9.4 ± 1.0 mm to 12.0 ± 3.3 mm, $p=0.019$) and mean posterior wall
218 thickness (9.8 ± 1.4 mm to 10.9 ± 3.3 mm, $p=0.147$). There was a significant increase in the
219 proportion of ATTRv-CM patients who developed left atrium dilation at follow-up compared to
220 baseline (63.6% vs 9.1%, $p=0.008$). Notably, 3 developed biatrial dilation during follow-up

221 (p=0.038). Among the 43 patients who did not develop ATTRv-CM by pre-specified criteria
222 (**Table S3**), there were expectedly no differences between any of the echocardiographic
223 parameters during follow-up as compared to baseline.

224

225 *Predictors of cardiac disease penetrance*

226 Baseline characteristics were selected to evaluate for an association with ATTRv-CM
227 development using Firth's penalized logistic regression (**Table S4**). The proband's age at the time
228 of diagnosis (p-value = 0.0076) and AI-ECG amyloid probability (p-value = 0.0041) were
229 associated with the development of ATTRv-CM. Next, a composite score was calculated that
230 combined all the selected baseline characteristics to evaluate its predictive value for ATTRv-CM
231 development. A Ridge penalized logistic regression was fitted using the disease development as a
232 dependent variable and those baseline characteristics as independent variables. We use the
233 estimated predictor of the fitted model as the composite score. We use the precision-recall
234 analysis to evaluate the prediction performance of the composite score. The estimated AUC
235 under the precision-recall curve from repeated cross-validation was 0.65, which indicated a
236 prediction effect of those variables for ATTRv-CM development.

237 By fitting Cox proportional-hazard regressions, patient's age (HR: 1.09, 95%: 1.01, 1.17,
238 p=0.0246), proband's age of diagnosis (HR: 0.91, 95%: 0.86, 0.98, p=0.0096), NTproBNP (HR:
239 1.00, 95%: 1.00, 1.01, p=0.0119), scaled AI ECG probability of ATTRv-CM (HR: 1.04, 95% CI:
240 1.01-1.07, p=0.0091), proband's neurological involvement (HR: 0.23, 95% CI: 0.07-0.83,
241 p=0.0244), and NTproBNP (HR: 1.01, 95% CI: 1.00-1.01, p=0.0187) were associated with the
242 time to ATTR-CM development (**Table 5**). However, after adjusting for multiple testing these
243 associations were not statistically significant.

244

245 **Discussion**

246 This study, the largest of its kind to describe ATTRv G+/P- carriers, also sheds light on the
247 complex dynamics of cardiac disease penetrance and expressivity in ATTRv, that could help
248 counsel these individuals and may guide informed decision-making regarding the timing of
249 initiating medical therapy. The observed cardiac penetrance rate of 22% over a median 6.8-year
250 follow-up period and its age-dependency, underscores the latency and variable nature of disease
251 manifestation among *TTR* variant carriers lacking structural evidence of CM at baseline. This
252 study also provides insight into the evolution of cardiac morphology and function as assessed by
253 echocardiography in this genetically diverse group of *TTR* carriers. Moreover, we observed that
254 the proband's age of diagnosis impacts on disease penetrance in their family members, the older
255 the age at diagnosis of the proband, the lower the probability of developing amyloidosis in
256 family members. We also generated the hypothesis of the potential use of AI-enabled ECG
257 screening at baseline as a non-invasive method for predicting ATTRv-CM penetrance. The AI
258 ECG screening tool offers a promising approach to risk stratification, perhaps enabling a
259 precision medicine approach to attenuate disease progression and improve patient outcomes.
260 Larger studies are needed to validate our exploratory observations.

261 Among genetic cardiomyopathies, the time from being diagnosed with a P/LP to
262 developing the disease is highly variable and often undefined.²¹⁻²⁴ A Large dataset demonstrated
263 that the frequency of a P/LP *TTR* variant is not so rare (approximately 1 in 1000 individuals).²⁵
264 The penetrance of ATTRv manifesting specifically as peripheral neuropathy is also variable in
265 different geographical regions and among families.²⁶⁻²⁸ Similarly, ATTRv peripheral neuropathy
266 is also characterized by incomplete cardiac penetrance and variable expressivity.⁴ A relationship

267 between age at diagnosis and disease penetrance has been described in this disease, although the
268 underlying age-dependent mechanisms are unknown.²⁹ Male sex has also been associated with
269 an increased risk for peripheral neuropathy disease penetrance in ATTRV30M carriers.²⁶

270 The natural history of *TTR* variant carriers has been previously described in results of an
271 observational survey but was based on occurrence of symptoms alone.³⁰ The outcomes of
272 “asymptomatic” patients (defined as absence of heart failure symptoms) with echocardiographic
273 evidence of ATTR-CM at baseline have also been previously described,³¹ and individuals carriers
274 of a P/LP *TTR* variant enrolled in the United Kingdom Biobank were found to be at higher risk
275 of heart failure.²⁵ However, information regarding ATTRv cardiac disease penetrance and
276 expressivity based on cardiac imaging in G+/P- family members is largely unknown.³² In the
277 Atherosclerosis Risk in Communities study, V122I *TTR* variant Black carriers (n=124) were
278 found to be at an increased risk of incident heart failure as compared to non-carriers over 21.5
279 years of follow-up.³³ Recently, V122I carriers who were predominately Black were described to
280 have a higher risk of all-cause mortality and heart failure hospitalizations, particularly driven by
281 heart failure with reduced EF, compared to non-carrier controls.³⁴ However, in both these studies
282 whether CA was present at baseline and whether heart failure occurred due to CA or other causes
283 such as coronary artery disease or hypertension is unknown. Furthermore, White subjects were
284 not studied given that the V122I variant is predominantly present in Blacks. Our study addresses
285 these limitations by describing the disease-specific natural history of hereditary ATTR confirmed
286 by imaging in G+P- patients who mostly had variants other than V122I.

287 It is relevant to highlight that 18% of our overall cohort of family members had a history
288 of clinically diagnosed peripheral neuropathy at baseline and the nerve/skin biopsy, when
289 performed, was most likely to be negative for amyloid deposition. The lack of sensitivity of the

290 nerve/skin biopsies for amyloid maybe due to the multifocal amyloid deposition process, the
291 early stage of the disease, and the possibility of peripheral neuropathy due to related
292 comorbidities (three patients with negative biopsy had concomitant diabetes mellitus).^{35,36}
293 However, the high prevalence and progression of peripheral neuropathy underscores the potential
294 systemic nature of ATTRv amyloidosis and the importance of considering extracardiac
295 manifestations in the risk assessment of these individuals. Despite we were not powered to
296 predict the development of cardiac disease based on extracardiac manifestation, the presence of
297 these extracardiac clinical manifestations should always raise the suspicion of systemic
298 amyloidosis.

299 Increased LV wall thickness, a classic echocardiographic feature of CA, and a reduction
300 in LVEF were observed but the latter variable remained within normal limits in G+/P- family
301 members LVEF. Sensitive echocardiographic deformation parameters such as myocardial strain
302 have been proposed to detect early involvement of the heart in amyloidosis. However, these
303 values remained within the normal range in our population. Among the seven patients with
304 abnormal global longitudinal strain at baseline, ATTRv-CM was diagnosed only in one case
305 during follow-up. Therefore, global longitudinal strain may not be indicative of subsequent
306 cardiac involvement in our population. Myocardial deformation echocardiographic imaging has
307 primarily been validated in cohorts with some grade of increased myocardial wall thickness and
308 whether this echocardiographic parameter could be useful in the early identification of ATTR-
309 CM in a G+/P- population prior to this study is unknown.³⁷ Moreover, we found that the age at
310 which the proband is diagnosed with ATTRv influences cardiac penetrance in family members.
311 This age-dependent penetrance finding in the proband aligns with the recommendation of

312 beginning disease assessment in family members, 10 years before the affected proband's age of
313 disease onset.^{10,38}

314 It is unknown whether and when to initiate newer therapy for ATTR amyloidosis in G+P-
315 patients representing an unmet need in clinical practice. Our findings suggest that G+P-
316 individuals with a positive AI-ECG and with an affected proband who was diagnosed at a
317 younger age have a higher probability of developing CM. Patients with high AI-ECG probability
318 may warrant more frequent follow-up with multimodality imaging, and cardiac biopsy may be
319 indicated if imaging is inconclusive especially if patients are symptomatic to consider initiation
320 of therapy.

321

322 *Patient's perspective*

323 Returning genetic testing results can be emotionally and logistically challenging for both family
324 members and healthcare providers given the uncertainty in outcomes. Genetic testing results
325 might have a profound impact on individuals and families, highlighting the need for such studies
326 and high-touch methods such as one-on-one genetic counseling. We hope our study with others
327 will help inform not only the clinicians who will encounter these patients but also the patients
328 themselves.

329

330 *Limitations*

331 A limitation of our study includes a relatively small sample size which is an inherent limitation
332 of rare diseases, although it is the largest study of *TTR* P/LP variant carriers with longitudinal
333 cardiac imaging follow-up that provides information on cardiac penetrance of ATTRv in the
334 absence of clinically discernible cardiac disease. Although a longer period of follow-up may

335 have yielded a higher cardiac disease penetrance, this study with a median 6.8-year follow-up
336 period provides a reasonable estimate of disease risk. Furthermore, less than half had PYP
337 scintigraphy, largely driven by the period of the study, which is known to be more sensitive than
338 echocardiograms. Perhaps the cardiac phenotype penetrance might be even higher than what we
339 observed. Larger cohorts will be required to validate our findings such as the use of AI-ECG to
340 identify those at risk for ATTRv-CM development to enable early disease detection and
341 intervention.

342

343 *Conclusion*

344 In conclusion, the 10-year estimated risk of ATTRv-CM development in G+P- family members
345 is high at 29.5%, and the most common echocardiographic features that characterize CM
346 development are increased LV wall thickness and left atrial dilation. The risk of developing CM
347 in ATTRv family members appears to be proband age-of-disease dependent and could be
348 predicted by baseline AI ECG. These findings describe the high incidence of CA and the
349 possibility of risk stratifying ATTRv G+P- patients not only to assist in counseling family
350 members but also to provide guidance to clinicians regarding the timing of initiating appropriate
351 but expensive therapy for ATTRv-CM. Further validation of our exploratory analysis results in
352 larger cohorts is needed.

353

354 **Sources of Funding**

355 Dr. Luca Fazzini received a grant funded by the Italian Society of Cardiology and Bruno
356 Farmaceutici during the research fellowship at Mayo Clinic, Rochester.

357

358 **Disclosures**

359 None.

360

361 **Supplemental Material**

362 Tables S1-S4

363 **References**

- 364 1. Pereira NL, Grogan M, Dec GW. Spectrum of restrictive and
365 infiltrative cardiomyopathies: Part 1 of a 2-Part Series. *J Am Coll Cardiol*. 2018;71:1130-
366 1148. doi: 10.1016/j.jacc.2018.01.016
- 367 2. Pereira NL, Grogan M, Dec GW. Spectrum of restrictive and
368 infiltrative cardiomyopathies: Part 2 of a 2-Part Series. *J Am Coll Cardiol*. 2018;71:1149-
369 1166. doi: 10.1016/j.jacc.2018.01.017
- 370 3. Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. *Cardiovasc Res*.
371 2023;118:3517-3535. doi: 10.1093/cvr/cvac119
- 372 4. Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO,
373 Dember LM, Frantz JG, Hershberger RE, Maurer MS, et al. 2023 ACC expert consensus
374 decision pathway on comprehensive multidisciplinary care for the patient with cardiac
375 amyloidosis. *J Am Coll Cardiol*. 2023;81:1076-1126. doi: doi:10.1016/j.jacc.2022.11.022
- 376 5. Buxbaum JN, Dispenzieri A, Eisenberg DS, Fändrich M, Merlini G, Saraiva MJM,
377 Sekijima Y, Westermark P. Amyloid nomenclature 2022: update, novel proteins, and
378 recommendations by the International Society of Amyloidosis (ISA) Nomenclature
379 Committee. *Amyloid*. 2022;29:213-219. doi: 10.1080/13506129.2022.2147636
- 380 6. Mutations in hereditary amyloidosis. [Internet]. 2023. Available from:
381 <http://www.amyloidosismutations.com/>. In.
- 382 7. Buxbaum JN, Ruberg FL. Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-
383 dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause
384 of significant heart disease in elderly African Americans. *Genet Med*. 2017;19:733-742.
385 doi: <https://doi.org/10.1038/gim.2016.200>

- 386 8. Ingenbleek Y, Young V. Transthyretin (prealbumin) in health and disease: nutritional
387 implications. *Annu Rev Nutr.* 1994;14:495-533. doi:
388 10.1146/annurev.nu.14.070194.002431
- 389 9. Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, Judge DP,
390 Lenihan DJ, Gottlieb SS, Shah SJ, et al. Genotype and phenotype of transthyretin cardiac
391 amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). *J Am Coll Cardiol.*
392 2016;68:161-172. doi: 10.1016/j.jacc.2016.03.596
- 393 10. Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ,
394 Nair AP, Nativi-Nicolau J, Ruberg FL. Cardiac amyloidosis: Evolving diagnosis and
395 management: A scientific statement from the American Heart Association. *Circulation.*
396 2020;142:e7-e22. doi: 10.1161/cir.0000000000000792
- 397 11. Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F, Biagini E, Lorenzini M,
398 Grigioni F, Leone O, et al. Disease profile and differential diagnosis of hereditary
399 transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian
400 perspective. *Eur Heart J.* 2013;34:520-528. doi: 10.1093/eurheartj/ehs123
- 401 12. Sekijima Y. Hereditary transthyretin amyloidosis. In: Adam MP, Feldman J, Mirzaa GM,
402 Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, eds. *GeneReviews*(®).
403 Seattle (WA): University of Washington, Seattle. Copyright © 1993-2024, University of
404 Washington, Seattle. GeneReviews is a registered trademark of the University of
405 Washington, Seattle. All rights reserved.; 1993.
- 406 13. Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, Burazor I, Caforio
407 ALP, Damy T, Eriksson U, et al. Diagnosis and treatment of cardiac amyloidosis. A

- 408 position statement of the European Society of Cardiology Working Group on Myocardial
409 and Pericardial Diseases. *Eur J Heart Fail.* 2021;23:512-526. doi: 10.1002/ejhf.2140
- 410 14. Yilmaz A, Bauersachs J, Bengel F, Büchel R, Kindermann I, Klingel K, Knebel F, Meder
411 B, Morbach C, Nagel E, et al. Diagnosis and treatment of cardiac amyloidosis: position
412 statement of the German Cardiac Society (DGK). *Clin Res Cardiol.* 2021;110:479-506.
413 doi: 10.1007/s00392-020-01799-3
- 414 15. Fine NM, Davis MK, Anderson K, Delgado DH, Giraldeau G, Kitchlu A, Massie R,
415 Narayan J, Swiggum E, Venner CP, et al. Canadian Cardiovascular Society/Canadian
416 Heart Failure Society joint position statement on the evaluation and management of
417 patients with cardiac amyloidosis. *Can J Cardiol.* 2020;36:322-334. doi:
418 10.1016/j.cjca.2019.12.034
- 419 16. Musunuru K, Hershberger RE, Day SM, Klinedinst NJ, Landstrom AP, Parikh VN,
420 Prakash S, Semsarian C, Sturm AC. Genetic testing for inherited cardiovascular diseases:
421 A scientific statement from the American Heart Association. *Circ Genom Precis Med.*
422 2020;13:e000067. doi: 10.1161/hcg.0000000000000067
- 423 17. Cuddy SAM, Chetrit M, Jankowski M, Desai M, Falk RH, Weiner RB, Klein AL, Phelan
424 D, Grogan M. Practical points for echocardiography in cardiac amyloidosis. *J Am Soc*
425 *Echocardiogr.* 2022;35:A31-a40. doi: 10.1016/j.echo.2022.06.006
- 426 18. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon
427 E, Spector E, et al. Standards and guidelines for the interpretation of sequence variants: a
428 joint consensus recommendation of the American College of Medical Genetics and
429 Genomics and the Association for Molecular Pathology. *Genet Med.* 2015;17:405-424.
430 doi: 10.1038/gim.2015.30

- 431 19. Grogan M, Lopez-Jimenez F, Cohen-Shelly M, Dispenzieri A, Attia ZI, Abou Ezzedine
432 OF, Lin G, Kapa S, Borgeson DD, Friedman PA, et al. Artificial intelligence-enhanced
433 electrocardiogram for the early detection of cardiac amyloidosis. *Mayo Clin Proc.*
434 2021;96:2768-2778. doi: 10.1016/j.mayocp.2021.04.023
- 435 20. Harmon DM, Mangold K, Suarez AB, Scott CG, Murphree DH, Malik A, Attia ZI,
436 Lopez-Jimenez F, Friedman PA, Dispenzieri A, et al. Postdevelopment performance and
437 validation of the artificial intelligence-enhanced electrocardiogram for detection of
438 cardiac amyloidosis. *JACC: Advances.* 2023;2:100612. doi:
439 doi:10.1016/j.jacadv.2023.100612
- 440 21. Topriceanu CC, Pereira AC, Moon JC, Captur G, Ho CY. Meta-analysis of penetrance
441 and systematic review on transition to disease in genetic hypertrophic cardiomyopathy.
442 *Circulation.* 2024;149:107-123. doi: 10.1161/circulationaha.123.065987
- 443 22. Shah RA, Asatryan B, Sharaf Dabbagh G, Aung N, Khanji MY, Lopes LR, van
444 Duijvenboden S, Holmes A, Muser D, Landstrom AP, et al. Frequency, penetrance, and
445 variable expressivity of dilated cardiomyopathy-associated putative pathogenic gene
446 variants in UK Biobank participants. *Circulation.* 2022;146:110-124. doi:
447 10.1161/circulationaha.121.058143
- 448 23. McGurk KA, Zhang X, Theotokis P, Thomson K, Harper A, Buchan RJ, Mazaika E,
449 Ormondroyd E, Wright WT, Macaya D, et al. The penetrance of rare variants in
450 cardiomyopathy-associated genes: A cross-sectional approach to estimating penetrance
451 for secondary findings. *Am J Hum Genet.* 2023;110:1482-1495. doi:
452 10.1016/j.ajhg.2023.08.003

- 453 24. Rosenbaum AN, Agre KE, Pereira NL. Genetics of dilated cardiomyopathy: practical
454 implications for heart failure management. *Nat Rev Cardiol.* 2020;17:286-297. doi:
455 10.1038/s41569-019-0284-0
- 456 25. Aung N, Nicholls HL, Chahal CAA, Khanji MY, Rauseo E, Chadalavada S, Petersen SE,
457 Munroe PB, Elliott PM, Lopes LR. Prevalence, cardiac phenotype, and outcomes of
458 transthyretin variants in the UK Biobank population. *JAMA Cardiol.* 2024. doi:
459 10.1001/jamacardio.2024.2190
- 460 26. Gorram F, Olsson M, Alarcon F, Nuel G, Anan I, Planté-Bordeneuve V. New data on the
461 genetic profile and penetrance of hereditary Val30Met transthyretin amyloidosis in
462 Sweden. *Amyloid.* 2021;28:84-90. doi: 10.1080/13506129.2020.1841623
- 463 27. Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pellié C, Planté-Bordeneuve V.
464 Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the
465 Swedish population. *Amyloid.* 2008;15:181-186. doi: 10.1080/13506120802193720
- 466 28. Planté-Bordeneuve V, Carayol J, Ferreira A, Adams D, Clerget-Darpoux F, Misrahi M,
467 Said G, Bonaïti-Pellié C. Genetic study of transthyretin amyloid neuropathies: carrier
468 risks among French and Portuguese families. *J Med Genet.* 2003;40:e120. doi:
469 10.1136/jmg.40.11.e120
- 470 29. Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. *Lancet Neurol.*
471 2011;10:1086-1097. doi: 10.1016/s1474-4422(11)70246-0
- 472 30. Coelho T, Conceição I, Waddington-Cruz M, Keohane D, Sultan MB, Chapman D,
473 Amass L. A natural history analysis of asymptomatic TTR gene carriers as they develop
474 symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes
475 Survey (THAOS). *Amyloid.* 2022;29:228-236. doi: 10.1080/13506129.2022.2070470

- 476 31. Gonzalez-Lopez E, Escobar-Lopez L, Obici L, Saturi G, Bezard M, Saith SE,
477 AbouEzzeddine OF, Mussinelli R, Gagliardi C, Kharoubi M, et al. Prognosis of
478 transthyretin cardiac amyloidosis without heart failure symptoms. *JACC CardioOncol.*
479 2022;4:442-454. doi: 10.1016/j.jacc.2022.07.007
- 480 32. Chandrashekar P, Alhuneafat L, Mannello M, Al-Rashdan L, Kim MM, Dungu J,
481 Alexander K, Masri A. Prevalence and outcomes of p.Val142Ile *TTR* amyloidosis
482 cardiomyopathy: A systematic review. *Circ Genom Precis Med.* 2021;14:e003356. doi:
483 doi:10.1161/CIRCGEN.121.003356
- 484 33. Quarta CC, Buxbaum JN, Shah AM, Falk RH, Claggett B, Kitzman DW, Mosley TH,
485 Butler KR, Boerwinkle E, Solomon SD. The amyloidogenic V122I transthyretin variant
486 in elderly Black Americans. *New Engl J Med.* 2015;372:21-29. doi:
487 10.1056/NEJMoa1404852
- 488 34. Selvaraj S, Claggett B, Shah SH, Mentz RJ, Khouri MG, Manichaikul AW, Khan SS,
489 Rich SS, Mosley TH, Levitan EB, et al. Cardiovascular burden of the V142I transthyretin
490 variant. *JAMA.* 2024;331:1824-1833. doi: 10.1001/jama.2024.4467
- 491 35. Freeman R, Gonzalez-Duarte A, Barroso F, Campagnolo M, Rajan S, Garcia J, Kim JY,
492 Wang N, Orellana L, Gibbons C. Cutaneous amyloid is a biomarker in early ATTRv
493 neuropathy and progresses across disease stages. *Ann Clin Transl Neurol.* 2022;9:1370-
494 1383. doi: 10.1002/acn3.51636
- 495 36. Said G. Indications and usefulness of nerve biopsy. *Arch Neurol.* 2002;59:1532-1535.
496 doi: 10.1001/archneur.59.10.1532
- 497 37. Pagourelis ED, Mirea O, Duchenne J, Van Cleemput J, Delforge M, Bogaert J,
498 Kuznetsova T, Voigt JU. Echo parameters for differential diagnosis in cardiac

499 amyloidosis: A head-to-head comparison of deformation and nondeformation parameters.
500 *Circ Cardiovasc Imaging*. 2017;10:e005588. doi: 10.1161/circimaging.116.005588
501 38. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid
502 cardiomyopathy: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2019;73:2872-2891.
503 doi: 10.1016/j.jacc.2019.04.003
504
505
506

507 **Table 1. Baseline characteristics of the overall G+/P- ATTRv cohort.**
508

| | Overall (n=85) |
|--|---------------------|
| Age (years) | 48.5 (11.7) |
| Male sex n (%) | 33 (39) |
| White n (%) | 77 (91) |
| Proband`s cardiac involvement n (%) | 47 (55) |
| Proband`s neurological involvement n (%) | 51 (60) |
| Proband`s organ involvement unknown n (%) | 10 (12) |
| First-degree relatives, n (%) | 63 (74) |
| Second-degree relatives, n (%) | 22 (26) |
| Blood test | |
| WBC (x10 ³ /μL) ^a | 6.1 (5.1-6.9) |
| Hb (g/dL) | 13.9 (1.4) |
| PLT (x10 ³ /μL) ^a | 231.0 (208.0-251.5) |
| Positive troponin n (%) | 12 (17) |
| NTproBNP (pg/ml) ^a | 51.0 (25.0-88.0) |
| Comorbidities | |
| Spinal stenosis n (%) | 2 (2) |
| Peripheral neuropathy n (%) | 15 (18) |
| CKD n (%) | 1 (1) |
| Bilateral carpal tunnel syndrome n (%) | 13 (15) |
| Pacemaker n (%) | 1 (1) |
| Syncope n (%) | 2 (2) |
| ECG | |
| Atrial fibrillation n (%) | 3 (4) |
| AVB n (%) | 3 (4) |
| Low voltage n (%) | 1 (1) |
| Pseudo-infarct pattern n (%) | 3 (4) |
| AI amyloid probability above threshold n (%) | 5 (6) |
| Imaging | |
| Echocardiography n (%) | 80 (94) |
| PYP scintigraphy n (%) | 34 (40) |
| Cardiac Magnetic Resonance n (%) | 4 (5) |
| Baseline Echocardiographic Features | |
| LVEF | 62.6 (7.4) |
| Posterior wall thickness (mm) | 9.1 (1.4) |
| Septal wall thickness (mm) | 9.3 (1.5) |

| | |
|---------------------------|-------------|
| LVEDV (ml) | 127 (25.7) |
| LA dilation n (%) | 7 (10) |
| Biatrial dilation n (%) | 2 (3) |
| LAVI (ml/m ²) | 28 (8.5) |
| RV dysfunction n (%) | 2 (3) |
| RVSP (mmHg) | 27.5 (5.2) |
| E/e`*` | 7.7 (2.7) |
| LV GLS (%) | -20.5 (2.6) |

Gene variants

| | |
|-----------------|---------|
| Val30Met n (%) | 25 (29) |
| Thr60Ala n (%) | 24 (28) |
| Val122Ile n (%) | 8 (9) |
| Ile107Val n (%) | 6 (7) |
| Other n (%) | 22 (26) |

509

510

511 AI: artificial intelligence. AVB: atrioventricular block. CKD: chronic kidney disease. GLS: left
512 ventricular global longitudinal strain. LVEDV: left ventricle end-diastolic volume. LVEF: left ventricle
513 ejection fraction. LA: left atrium. LAVI: left atrium volume index. PYP: pyrophosphates. RV: right
514 ventricle. RVSP: right ventricle systolic pressure.

515 *: We reported the mean between septal and lateral E/e` when both were available. If lateral E/e` was not
516 available, the only septal E/e` was reported.

517 Data represent mean (standard deviation, SD) or number (percentage) unless otherwise specified.

518 a: Data represent median (1st quantile, 3rd quantile).

519

520

521 **Table 2. Clinical and echocardiographic characteristics in G+/P- ATTRv carriers who had follow-**
 522 **up data available (n=55).**

| | Baseline | Follow-up | Difference | p-value# |
|---|-------------|------------|-------------------|----------|
| Comorbidities | | | | |
| Spinal stenosis n (%) | 2 (3.6) | 6 (10.9) | 7.3 (-2.3, 16.9) | 0.142 |
| Peripheral neuropathy n (%) | 10 (18.2) | 24 (43.6) | 25.5 (8.9, 42.1) | 0.004 |
| CKD n (%) | 1 (1.8) | 6 (10.9) | 9.1 (0.1, 18.1) | 0.051 |
| Bilateral carpal tunnel syndrome n (%) | 9 (16.4) | 16 (29.1) | 12.7 (-2.8, 28.2) | 0.111 |
| Atrial fibrillation n (%) | 3 (5.5) | 8 (14.5) | 9.1 (-2, 20.2) | 0.112 |
| Pacemaker n (%) | 1 (1.8) | 1 (1.8) | - | - |
| Syncope n (%) | 2 (3.6) | 8 (14.5) | 10.9 (0.4, 21.5) | 0.047 |
| Echocardiography | | | | |
| LVEF | 63.3 (4.3) | 61.2 (3.6) | -2 (-3.6, -0.4) | 0.014 |
| Septal wall thickness (mm) | 9.4 (1.6) | 10.2 (2.4) | 0.7 (0, 1.3) | 0.037 |
| Abnormal septal wall thickness n (%) | 0 (0) | 4 (8.7) | 8.7 (0.6, 16.8) | 0.035 |
| Posterior wall thickness (mm) | 9.3 (1.5) | 9.2 (2.2) | 0 (-0.5, 0.6) | 0.853 |
| Abnormal posterior wall thickness n (%) | 0 (0) | 2 (4.5) | 4.5 (-1.6, 10.7) | 0.128 |
| Left atrium volume index (ml/m ²) | 28.5 (9.6) | 29.2 (6.8) | 1.1 (-2.3, 4.5) | 0.518 |
| Left atrium dilation n (%) | 5 (10.2) | 14 (29.8) | 19.6 (4, 35.2) | 0.016 |
| Biatrial dilation n (%) | 2 (4.3) | 4 (8.9) | 4.6 (-5.5, 14.8) | 0.368 |
| E/e`* | 7.4 (2.2) | 7.2 (2.4) | 0.3 (-0.6, 1.1) | 0.558 |
| LV GLS (%) | -19.8 (2.7) | -20.4 (3) | -0.6 (-1.5, 0.3) | 0.205 |

523

524 CKD: chronic kidney disease. GLS: left ventricular global longitudinal strain. LV: left ventricular. LVEF:
 525 left ventricle ejection fraction.

526 *: We reported the mean between septal and lateral E/e` when both were available. If lateral E/e` was not
 527 available, the only septal E/e` was reported.

528 Data represent mean (standard deviation, SD) or number (percentage) unless otherwise specified.

529 The proportional difference (95% confidence interval, CI) for binary variables or the mean difference
 530 (95% CI) for continuous variables are reported in the column named by "Difference".

531 For binary variables, the proportional difference between follow up and baseline levels was tested if it is
 532 different from 0. For continuous variables, paired t test was used to test if the variable's mean is different
 533 between baseline and follow up time. Two-sided tests were used.

534 #: The raw p-value obtained from statistical tests are reported. Bonferroni correction was used to account
 535 for multiple testing. Therefore, the significance level is 0.05, and the adjusted significance level is 0.05/16
 536 = 0.00313.

537

538 **Table 3. Estimated penetrance for developing cardiac amyloidosis based on various G+/P- ATTRv**
539 **carrier age groups.**

| Age Groups* | Total No. of Patients | Penetrance | 95% CI |
|-------------|-----------------------|------------|--------------|
| <= 50 years | 18 | 0.11 | (0.03, 0.33) |
| 50-60 years | 15 | 0.13 | (0.04, 0.38) |
| 60-70 years | 15 | 0.33 | (0.15, 0.58) |
| >= 70 years | 7 | 0.43 | (0.16, 0.75) |

540 *: the age at the cardiac amyloidosis diagnosis or at the last follow-up.

541

542 **Table 4. Differences between echocardiographic characteristics at baseline and last follow-up**
 543 **among G+/P- ATTRv carriers who developed CA (n = 12).**

| | Baseline | At CA diagnosis | Difference | p-value# |
|---|-------------|-----------------|-------------------|----------|
| LVEF | 65.2 (3.3) | 60.3 (5.3) | -5.2 (-9.6, -0.8) | 0.026 |
| Septal wall thickness (mm) | 9.4 (1) | 12 (3.3) | 2.7 (0.6, 4.8) | 0.019 |
| Abnormal septal wall thickness n (%) | 0 (0) | 4 (36.4) | 36.4 (7.9, 64.8) | 0.034 |
| Posterior wall thickness (mm) | 9.8 (1.4) | 10.9 (3.3) | 1.4 (-0.6, 3.4) | 0.147 |
| Abnormal posterior wall thickness n (%) | 0 (0) | 2 (22.2) | 22.2 (-4.9, 49.4) | 0.099 |
| Left atrium volume index (ml/m ²) | 28.2 (10.6) | 33.3 (8.1) | 6.3 (-3.5, 16.1) | 0.173 |
| Left atrium dilation n (%) | 1 (9.1) | 7 (63.6) | 54.5 (21.4, 87.7) | 0.008 |
| Biatrial dilation n (%) | 0 (0) | 3 (33.3) | 33.3 (2.5, 64.1) | 0.038 |
| E/e`* | 8.1 (3.6) | 8.6 (4) | 2.2 (-1.4, 5.8) | 0.198 |
| LV GLS (%) | -19.3 (3.2) | -18 (4.1) | 0 (-3.4, 3.5) | 0.966 |

544

545 GLS: left ventricular global longitudinal strain. LV: left ventricular. LVEF: left ventricle ejection fraction.

546 *: We reported the mean between septal and lateral E/e` when both were available. If lateral E/e` was not
 547 available, the only septal E/e` was reported.

548 Data represent mean (standard deviation, SD) or number (percentage) unless otherwise specified.

549 The proportional difference (95% confidence interval, CI) for binary variables or the mean difference
 550 (95% CI) for continuous variables are reported in the column named by “Difference”.

551 For binary variables, the proportional difference between follow up and baseline levels was tested if it is
 552 different from 0. For continuous variables, paired t test was used to test if the variable’s mean is different
 553 between baseline and follow up time. Tow-sided tests were used.

554 #: The raw p-value obtained from statistical tests are reported. Bonferroni correction was used to account
 555 for multiple testing. Therefore, the significance level is 0.05, and the adjusted significance level is 0.05/10
 556 = 0.005.

557

558

559 **Table 5. Association between baseline characteristics and ATTRv-CM development risk.**

| | Estimated HR | 95% CI | p-value# |
|----------------------------------|--------------|---------------|----------|
| Age (years) | 1.09 | (1.01,1.17) | 0.0246 |
| Male sex | 2.20 | (0.66, 7.33) | 0.1999 |
| Proband's age | 0.91 | (0.86, 0.98) | 0.0096 |
| Proband's cardiac involvement | 2.56 | (0.74, 8.80) | 0.1356 |
| Proband's neuro involvement | 0.23 | (0.07,0.83) | 0.0244 |
| NTproBNP (pg/ml) | 1.01 | (1.00,1.01) | 0.0187 |
| Peripheral neuropathy | 0.89 | (0.24, 3.36) | 0.8674 |
| Bilateral carpal tunnel syndrome | 3.78 | (0.89, 15.99) | 0.0705 |
| AI amyloid probability at ECG | 1.04 | (1.01, 1.07) | 0.0091 |
| LVEF | 1.01 | (0.89, 1.15) | 0.8778 |
| Posterior wall thickness (mm) | 1.41 | (0.86, 2.30) | 0.1736 |
| Septal wall thickness (mm) | 1.08 | (0.70, 1.66) | 0.7393 |
| Val30Met | 0.20 | (0.02, 1.56) | 0.1230 |
| Thr60Ala | 1.68 | (0.54, 5.23) | 0.3742 |
| Val122Ile | 4.96 | (0.91, 27.15) | 0.0648 |

560


561 AI: artificial intelligent; ECG: electrocardiogram; LVEF: left ventricle ejection fraction.

562 #: The raw p-value obtained from statistical tests are reported. Bonferroni correction was used to account
563 for multiple testing. Therefore, the significance level is 0.05, and the adjusted significance level is 0.05/15
564 = 0.003.

565

566

567 **Figure 1. Kaplan-Meier curve showing the 10-year risk of developing overt ATTRv-CM (29.5%,**
568 **95% CI: 7.9, 46.0).**



569

570